More than seven years after FDA was empowered to require Risk Evaluation and Mitigation Strategies to ensure that drugs’ benefits outweigh their risks, the agency is still struggling to figure out how much evidence is needed to scale back a REMS.
The apparent success of the REMS for Alexion Pharmaceuticals Inc.’s Soliris (eculizumab) shows the challenges FDA faces in determining...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?